Verdence Capital Advisors LLC Takes Position in Kenvue Inc. (NYSE:KVUE)

Verdence Capital Advisors LLC acquired a new position in Kenvue Inc. (NYSE:KVUE) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 27,038 shares of the company’s stock, valued at approximately $582,000.

Other large investors also recently added to or reduced their stakes in the company. Clearstead Advisors LLC purchased a new position in shares of Kenvue during the 3rd quarter worth $25,000. Planned Solutions Inc. bought a new stake in Kenvue during the fourth quarter valued at about $27,000. EverSource Wealth Advisors LLC purchased a new stake in Kenvue in the third quarter worth about $28,000. AdvisorNet Financial Inc bought a new position in shares of Kenvue in the third quarter worth about $28,000. Finally, Global Retirement Partners LLC purchased a new position in shares of Kenvue during the 3rd quarter valued at about $28,000. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on KVUE. The Goldman Sachs Group started coverage on shares of Kenvue in a report on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price for the company. Sanford C. Bernstein initiated coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective on the stock. Royal Bank of Canada dropped their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 9th. JPMorgan Chase & Co. decreased their price target on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. Finally, William Blair initiated coverage on Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $24.85.

Kenvue Stock Up 0.0 %

NYSE KVUE opened at $19.59 on Tuesday. The stock has a 50 day moving average price of $19.84 and a 200-day moving average price of $20.16. Kenvue Inc. has a one year low of $17.82 and a one year high of $27.80. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. The business had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. Kenvue’s revenue was down 2.7% compared to the same quarter last year. On average, equities analysts forecast that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, February 13th. This represents a $0.80 annualized dividend and a yield of 4.08%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.